Inactive Instrument

Highlights Aurinia Pharmaceuticals Inc. Toronto S.E.

Equities

AUP

CA05156V1022

Highlights

Unlock all the news: Be the first to know and act before the market!

Aurinia Pharmaceuticals Inc. Presents Safety and Efficacy Profile of LUPKYNIS® for People with Lupus Nephritis	Jun. 05	CI
Aurinia Pharmaceuticals Inc. Presented Results from the Analysis Showing Lupkynis A Cost-Effective Treatment for Lupus Nephritis Presented At National Kidney Foundation's Spring Clinical Meeting 2024	May. 14	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q1 Revenue $50.3M, vs. Street Est of $47.1M	May. 02	MT
Tranche Update on Aurinia Pharmaceuticals Inc.'s Equity Buyback Plan announced on February 15, 2024.	May. 02	CI
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 02	CI
Aurinia Pharmaceuticals Inc. Reiterates Revenue Guidance for the Fiscal Year 2024	May. 02	CI
Aurinia Pharmaceuticals Inc. Announces The U.S. Food & Drug Administration Approves Updated LUPKYNIS® Label to include Long-Term Data from the AURORA Clinical Program	Apr. 30	CI
Aurinia Pharmaceuticals Q4 Loss Widens, Revenue Increases; Concludes Strategic Review -- Shares Slump	Feb. 15	MT
Aurinia Pharmaceuticals Inc. announces an Equity Buyback for $150 million worth of its shares.	Feb. 15	CI
Earnings Flash (AUPH) AURINIA PHARMACEUTICALS Posts Q4 Revenue $45.1M, vs. Street Est of $45.2M	Feb. 15	MT
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 15	CI
Aurinia Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 15	CI
Aurinia Pharmaceuticals Inc. Provides Revenue Guidance for the Fiscal Year 2024	Feb. 15	CI
AURINIA PHARMACEUTICALS FINDS NO BUYER, TO ANNOUNCE $1…	Feb. 15	RE
Kidney drug developer Aurinia fails to clinch a sale, sources say	Feb. 15	RE
Aurinia Pharmaceuticals Inc. authorizes a Buyback Plan.	Feb. 14	CI
Aurinia Pharmaceuticals Reports Higher Q4, 2023 Preliminary Revenue; Shares Rise	Jan. 05	MT
Aurinia Pharmaceuticals Submits Investigational New Drug Application for AUR200	Dec. 20	MT
Aurinia Pharmaceuticals Inc. Submits IND Application to US Food & Drug Administration for AUR 200	Dec. 20	CI
Aurinia Pharmaceuticals Partner Otsuka Pharmaceutical Files New Drug Application For Voclosporin in Japan	Nov. 13	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Aurinia Pharmaceuticals Inc. Toronto S.E.

Equities

AUP

CA05156V1022

Highlights

Filters